Retour vers les projets


How to develop a treatment to ease neuropathic pains

At present time, doctors have very few therapeutic options to ease neuropathic pains. Current pharmacological treatments are very frequently linked to unwelcomed side effects. There is thus an important need of new and effective treatments causing little or zero side effects and not interacting with other medicines. Drawing on this, professors Jean-Jacques Bourguignon (Laboratoire d’Innovation Thérapeutique - UMR 7200 CNRS – Unistra) and Michel Barrot (Institut des Neurosciences Cellulaires et Intégratives – UPR 3212 CNRS) have identified a new action mechanism. They were able to characterize some compounds for their ability to block hyperalgesia (allodynia) induced in mice through injury of the sciatic nerve in the frame of a first stage of “pre-maturation” for an amount of 8,600€.

Today, the investment granted for the maturation will allow both research teams to:

  • characterize the most promising molecule for its properties in vitro and in vivo
  • generate the proof of concept of neuropathic pain in animal models

Investment: 315,000€ over a period of 18 months